- Conditions
- Healthy
- Interventions
- Raltegravir, Fosamprenavir, Ritonavir
- Drug
- Lead sponsor
- Garden State Infectious Disease Associates, PA
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Voorhees Township, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 618
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Overweight, Obesity, Type 2 Diabetes Mellitus
- Interventions
- NNC0662-3168 (Test product-A), Placebo matched to NNC0662-3168 (Test product-A), Active Comparator (Product-B)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Neuromuscular Blockade
- Interventions
- Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
- Conditions
- Healthy
- Interventions
- cangrelor, moxifloxacin, placebo
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy
- Interventions
- Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- HIV Infections
- Interventions
- Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Hamilton, New Jersey
- Conditions
- Diabetic Macular Edema
- Interventions
- Octreotide (drug), Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Renal Anemia
- Interventions
- AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
- Drug
- Lead sponsor
- Kind Pharmaceuticals LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, GS-3242, Lenacapavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Ft. Pierce, Florida • Houston, Texas
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Hepatic Impairment
- Interventions
- AG-120 (Ivosidenib)
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Lakewood, Colorado • Minneapolis, Minnesota
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Alzheimer Disease
- Interventions
- BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- COPD
- Interventions
- Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
- Combination Product
- Lead sponsor
- Phargentis SA
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
- Conditions
- Vaccine Response
- Interventions
- Atorvastatin, Quadrivalent seasonal influenza vaccine
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Anesthesia
- Interventions
- Thoracic epidural block, Electrical Nerve stimulation, Solution For Thoracic epidural block
- Procedure · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- Interventions
- DS3790a, Combination drug
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Substance Use Disorders
- Interventions
- Standard Contingency Management (CM), Enhanced Contingency Management (CM+)
- Behavioral
- Lead sponsor
- Oregon Social Learning Center
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-210, Gemcitabine, MMC
- Combination Product · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- Zibotentan/Dapagliflozin, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 1,835 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 64
- States / cities
- Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more
- Conditions
- Autonomic Nerve Block
- Interventions
- Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline
- Procedure
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
- Interventions
- filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 244
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Ganetespib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
- Conditions
- Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed
- Interventions
- rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
- Biological
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 41
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 34 more